Belite Bio, Inc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLTE research report →
Companybelitebio.com
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase.
- CEO
- Yu-Hsin Lin
- IPO
- 2022
- Employees
- 25
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $5.73B
- P/E
- -61.95
- P/S
- 0.00
- P/B
- 6.24
- EV/EBITDA
- -63.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -22.95%
- ROIC
- -10.92%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-77,611,000 · -114.73%
- EPS
- $-2.31 · -95.76%
- Op Income
- $-84,208,000
- FCF YoY
- -26.48%
Performance & Tape
- 52W High
- $200.00
- 52W Low
- $56.10
- 50D MA
- $160.50
- 200D MA
- $130.47
- Beta
- -1.19
- Avg Volume
- 157.02K
Get TickerSpark's AI analysis on BLTE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 26 | MATA NATHAN L. | sell | 226 |
| May 7, 26 | MATA NATHAN L. | sell | 428 |
| May 7, 26 | MATA NATHAN L. | sell | 3 |
| May 7, 26 | MATA NATHAN L. | sell | 9 |
| May 6, 26 | MATA NATHAN L. | sell | 8 |
| May 6, 26 | MATA NATHAN L. | sell | 424 |
| May 6, 26 | MATA NATHAN L. | sell | 128 |
| May 6, 26 | MATA NATHAN L. | sell | 240 |
| May 6, 26 | MATA NATHAN L. | sell | 100 |
| May 6, 26 | MATA NATHAN L. | sell | 100 |
Our BLTE Coverage
We haven't published any research on BLTE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLTE Report →